The aim of this study was to evaluate the modification in residual platelet reactivity by adjusting the prasugrel dose from 10 mg to 5 mg after the acute phase (1 month) of ACS. 450 patients were included receiving a loading dose of 60 mg followed by a month of 10 mg of prasugrel and randomized one month to continue with 10 mg or reduce the dose to 5 mg to complete one year.
Platelet reactivity was tested at baseline and 7 days after randomization. By reducing the dose, the residual platelet reactivity increased, however, is still under study if this modification can result in decreased of bleeding complications or an increase of ischemic events.
Nazario Carrabba
2014-05-22
Title: Prospective evaluation of on-prasugrel platelet reactivity over time in ACS patients treated with angioplasty: BLESS (BLeeding Events and maintenance doSe of praSugrel) pharmacodymamic study
